<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Delivery of inhaled medication in children</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Delivery of inhaled medication in children</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Delivery of inhaled medication in children</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ariel Berlinski, MD, FAAP, FAARC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gregory Redding, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Robert A Wood, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth TePas, MD, MS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 28, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The delivery of aerosolized medication is an important component of treatment for many respiratory disorders and is a critical aspect of asthma management in children [<a href="#rid1">1-15</a>]. A basic knowledge of the uses and limitations of aerosol delivery systems, the properties of effective aerosols, and the anatomic considerations affecting aerosol delivery in infants and children is essential to the optimal use of this therapeutic modality [<a href="#rid16">16-18</a>].</p><p>An overview of the delivery of inhaled medication in children is presented here. Specific aspects of medication delivery using nebulizers, pressurized metered dose inhalers (pMDIs) and soft mist inhalers (SMIs), and dry powder inhalers (DPIs) are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p>Delivery of aerosolized medications in adults is also reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a>.)</p><p class="headingAnchor" id="H5426205"><span class="h1">ADVANTAGES OF AEROSOLIZED DRUG DELIVERY</span><span class="headingEndMark"> — </span>There are several advantages to delivering drugs by aerosol rather than systemically:</p><p class="bulletIndent1"><span class="glyph">●</span>Delivery of agents directly to their sites of action decreases the dose required for therapeutic effect.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Faster onset of action (compared with intravenous delivery) of bronchodilating medications allows more rapid reversal of acute bronchoconstriction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced systemic bioavailability minimizes side effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Ability to achieve high in-situ drug concentrations.</p><p></p><p class="headingAnchor" id="H5426212"><span class="h1">TYPES OF AEROSOL DELIVERY DEVICES</span><span class="headingEndMark"> — </span>Three types of aerosol delivery devices are widely employed in the management of children with respiratory disease  (<a class="graphic graphic_table graphicRef52016 graphicRef71527" href="/z/d/graphic/52016.html" rel="external">table 1A-B</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Nebulizers, which use a jet flow of driving gas, ultrasound, or vibrating membrane to aerosolize medications</p><p class="bulletIndent1"><span class="glyph">●</span>Pressurized metered dose inhalers (pMDIs) and soft mist inhalers (SMIs)</p><p class="bulletIndent1"><span class="glyph">●</span>Dry powder inhalers (DPIs)</p><p></p><p>Specific issues related to the use of these devices are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p class="headingAnchor" id="H1893540854"><span class="h1">TYPES OF MEDICATIONS DELIVERED</span><span class="headingEndMark"> — </span>Glucocorticoids, bronchodilators, antibiotics, antivirals, pulmonary vasodilators, and mucolytic agents can be administered via aerosol using different aerosol-generating devices [<a href="#rid1">1-4</a>]. In addition, the inhalation route is also used for systemic delivery (insulin, opioids, and sedatives). Antifungals, immunosuppressants, and anticoagulants are used off label [<a href="#rid9">9,10</a>].</p><p class="headingAnchor" id="H2"><span class="h1">LUNG DISEASES MANAGED USING AEROSOL THERAPY</span><span class="headingEndMark"> — </span>A wide range of pediatric disorders can be treated effectively using aerosol therapy as a central component of management. Examples include:</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive airway diseases, including asthma, congenital emphysema, and bronchiectasis [<a href="#rid19">19</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Processes that result in acute upper airway obstruction, usually croup or postextubation upper-airway edema</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic lung diseases, including bronchopulmonary dysplasia and cystic fibrosis [<a href="#rid20">20</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tracheitis in tracheostomized children [<a href="#rid21">21</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pulmonary hypertension [<a href="#rid22">22</a>]</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Infectious diseases, including <em>Pneumocystis jirovecii</em> pneumonia (treatment and prophylaxis), respiratory syncytial virus infection, and some pulmonary fungal infections [<a href="#rid23">23-28</a>]</p><p></p><p>Less common off-label indications for aerosol therapy include intractable cough, which may respond to inhaled <a class="drug drug_pediatric" data-topicid="12551" href="/z/d/drug information/12551.html" rel="external">lidocaine</a>, and administration of analgesia in the setting of palliative care, using inhaled <a class="drug drug_pediatric" data-topicid="16024" href="/z/d/drug information/16024.html" rel="external">morphine</a> [<a href="#rid29">29-31</a>]. Aerosol delivery of gene constructs are under investigation for diseases such as cystic fibrosis [<a href="#rid9">9,11,32</a>].</p><p class="headingAnchor" id="H3"><span class="h1">PROPERTIES OF AN IDEAL AEROSOL THERAPY DEVICE</span><span class="headingEndMark"> — </span>The ideal aerosol delivery device varies depending upon the medication to be administered and the clinical situation. To maximize the advantages of inhaled medications described above, the device selected should:</p><p class="bulletIndent1"><span class="glyph">●</span>Deliver an adequate dose of medication to the lungs</p><p class="bulletIndent1"><span class="glyph">●</span>Minimize oropharyngeal deposition</p><p class="bulletIndent1"><span class="glyph">●</span>Minimize systemic side effects</p><p class="bulletIndent1"><span class="glyph">●</span>Match the needs of the patient</p><p class="bulletIndent1"><span class="glyph">●</span>Be acceptable and simple for the patient to use</p><p class="bulletIndent1"><span class="glyph">●</span>Be cost effective</p><p></p><p class="headingAnchor" id="H4"><span class="h1">FACTORS AFFECTING DRUG DEPOSITION</span><span class="headingEndMark"> — </span>A number of factors influence the ultimate amount of medication delivered to the appropriate anatomic region within the lung.</p><p class="headingAnchor" id="H5"><span class="h2">Properties of the device</span><span class="headingEndMark"> — </span>Devices vary greatly in their efficiencies in delivering particles to the lungs. From 0.5 to 60 percent of the total dose of medication is delivered to the peripheral airways when these devices are used optimally. (See  <a class="medical medical_review" href="/z/d/html/552.html" rel="external">"Delivery of inhaled medication in adults"</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Aerosol properties</span><span class="headingEndMark"> — </span>Pharmaceutical aerosols are characterized by measures of central tendency and dispersion. The former is the mass median aerodynamic diameter (MMAD), which represents the particle diameter at which half of the aerosol particles by mass are larger and half are smaller [<a href="#rid4">4,17,33,34</a>]. The geometric standard deviation (GSD) differentiates a monodisperse (GSD &lt;1.2) from a polydisperse aerosol (GSD &gt;1.2). The other parameter frequently described is the respirable fraction, which corresponds to the percent of particles &lt;5 micrometers. This is considered the fraction of aerosol likely to deposit in the lungs. However, some experts argue that smaller sizes are more optimal for infants and children.</p><p class="headingAnchor" id="H477114186"><span class="h2">Mechanisms of deposition</span><span class="headingEndMark"> — </span>There are three basic mechanisms of aerosol deposition: inertial impaction, gravitational sedimentation, and Brownian diffusion [<a href="#rid4">4,35,36</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Particles with an MMAD greater than 5 micrometers and those travelling at high velocity are deposited by impaction largely in the oropharynx. This is the rationale for using valved holding chambers or spacers with pressurized metered dose inhalers (pMDIs) to allow deceleration of the aerosol.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Particles with an MMAD between 3 and 5 micrometers are optimal for deposition in the proximal airways and are deposited largely by inertial impaction.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Particles with an MMAD between 0.5 and 3 micrometers are deposited in distal airways by gravitational sedimentation. This is the rationale for using a breath-holding maneuver to increase residence time when using pMDIs or dry powder inhalers (DPIs).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Particles with MMAD smaller than 0.5 micrometers are deposited at the alveolar level by random motion (Brownian diffusion).</p><p></p><p class="headingAnchor" id="H7"><span class="h2">Properties of medication to be delivered</span><span class="headingEndMark"> — </span>The ultimate effect of the dose is dependent upon the site of deposition of the drug within the lung, the rate of drug clearance from the airway, and the site of action of the medication [<a href="#rid35">35,37</a>]. To be effective, drugs must be able to withstand the shear forces required to generate the aerosol and often must penetrate the mucus layer and airway mucosa to reach their target receptors or cells.</p><p class="headingAnchor" id="H8"><span class="h2">Disease state and ventilatory pattern</span><span class="headingEndMark"> — </span>Anatomic and pathologic factors, as well as ventilatory patterns, alter the efficiency of aerosolized drug delivery. Aerosol particles may be deposited in the central, rather than lower, airways in diseases that are associated with decreased airway caliber such as asthma [<a href="#rid2">2,35</a>]. In a study of infants with acute bronchiolitis, only 1.5 percent of aerosolized drug released from the nebulizer was deposited in the lung and 0.6 percent penetrated to the peripheral airways [<a href="#rid38">38</a>].</p><p>Diseases causing mucus plugging or atelectasis, such as cystic fibrosis, may lead to reduction and marked heterogeneity in the distribution of particle deposition. Other factors such as tidal volume, breath-holding time, respiratory rate, and nose versus mouth breathing can dramatically alter the deposition of aerosolized particles in the lungs [<a href="#rid4">4,13,17,35,39</a>].</p><p class="headingAnchor" id="H9"><span class="h2">Patient technique, acceptance, and preference</span><span class="headingEndMark"> — </span>Improper technique is a common cause for a suboptimal response to aerosolized medication and worse outcomes [<a href="#rid40">40</a>], and poor understanding or acceptance may lead to nonadherence. Patient education and health care worker knowledge are essential for the effective use of any aerosol delivery device [<a href="#rid4">4,17</a>]. However, studies on inhaler technique show low rates of correct patient inhaler technique that are most likely due to poor knowledge on the subject by health care workers [<a href="#rid41">41,42</a>].</p><p>Rapid inspiration from pMDIs may increase inertial impaction of droplets in the central airways and decrease lung delivery. Many valved holding chambers incorporate a whistle to alert the patient that their inspiratory flow is too high (above 30 L/min). However, this feature is inaccurate and may falsely reassure patients that they are using the correct technique [<a href="#rid43">43</a>].</p><p>Review of inhaler technique at each encounter using the teach back method is recommended. Device selection is influenced by health care worker and patient/caregiver preferences, third-party-payer, drug availability, and patient characteristics that hinder the operation/use of certain inhalers (eg, weakness, severe arthritis or contractures, altered mental status).</p><p class="headingAnchor" id="H10"><span class="h1">SPECIAL CONSIDERATIONS IN INFANTS AND YOUNG CHILDREN</span></p><p class="headingAnchor" id="H516121784"><span class="h2">Anatomic and physiologic differences</span><span class="headingEndMark"> — </span>The delivery of aerosolized medication to infants and young children poses some challenges due to anatomic and physiologic differences in their respiratory systems compared with adults [<a href="#rid4">4</a>]. The anatomic differences from adults include a higher larynx, epiglottis closer to the palate, more collapsible pharynx and supraglottic tissues, and relatively larger tongue. Physiologically, children have faster breathing rates, lower tidal volumes, and shorter inspiratory times. The deposition of medication in peripheral airways and alveoli is reduced in infants and young children due to these anatomic and physiologic differences, which combine to lower the resident time of small particles in the airway [<a href="#rid3">3,4,13-15,44-46</a>].</p><p class="headingAnchor" id="H11"><span class="h2">Dose</span><span class="headingEndMark"> — </span>Data suggest that drug deposition in children older than five to six years of age is similar to that observed in adults, and identical doses in children and adults result in similar plasma concentrations [<a href="#rid37">37,47</a>]. Thus, aerosol doses generally do not need to be decreased, except possibly in infants and young children. However, it is probable that variability exists based upon the specific medication used, drug delivery technique (tidal volume breathing compared with inspiratory breath hold), and delivery device employed. These data support the concept that younger children self-adjust their dose [<a href="#rid48">48</a>].</p><p>The output of the aerosol-generating device may exceed inspiratory flow rate in children younger than six months of age, resulting in the loss of air entrainment (mixing of inspired air with nebulizer output) and a higher concentration of drug delivered [<a href="#rid46">46</a>]. Overall, this effect can lead to a higher inhaled dose per kilogram of body weight in the infant younger than six months of age, increasing the possibility of side effects, although increased side effects have not been reported in this age group, nor are there recommendations to decrease any drug dose because of this effect. However, if clinicians decide to decrease the dose, a reduction of the treatment time is preferred rather than a reduction in loading volume of the nebulizer [<a href="#rid49">49</a>].</p><p class="headingAnchor" id="H12"><span class="h2">Respiratory pattern</span><span class="headingEndMark"> — </span>Normal tidal breathing results in the most efficient delivery of aerosolized medications to the airways. Crying markedly reduces aerosol delivery to the lungs. Caregivers play a major role in keeping the infant calm during treatments [<a href="#rid50">50,51</a>]. Although in vitro studies suggested that administration of medication via a pressurized metered dose inhaler (pMDI) with valved holding chamber resulted in increased drug delivery, a "real-life" study in infants and children showed the opposite due to awakening and distress of the participants [<a href="#rid52">52,53</a>]. Thus, aerosol administration during sleep may be tried for uncooperative infants and children, but caregivers should be informed that the success rate may be low (ie, the infant may awaken and start crying).</p><p>The use of breath-actuated devices and dry powder inhalers (DPIs) requires inspiratory flows that are not achieved by infants and toddlers. Thus, these types of devices are not used in this age group. In addition, clinicians should verify that patients are able to open the valves of valved holding chambers and dosimetric nebulizers during inhalation [<a href="#rid4">4</a>]. (See  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Interface</span><span class="headingEndMark"> — </span>The interface between the aerosol-generating device and the patient is an important, and often overlooked, component of effective therapy. Administration of aerosols by a mouthpiece rather than a facemask is generally preferred to avoid facial and ocular exposure to inhaled medications [<a href="#rid54">54-56</a>]. Similar clinical responses have been reported for mouthpiece and facemask administration for bronchodilators in children with acute asthma [<a href="#rid57">57</a>] and for nebulized <a class="drug drug_pediatric" data-topicid="13096" href="/z/d/drug information/13096.html" rel="external">budesonide</a> in chronic asthma [<a href="#rid58">58</a>]. However, most children are not able to reliably breathe through a mouthpiece until approximately four years of age, and patient technique with a mouthpiece must be assessed prior to switching from a facemask [<a href="#rid4">4,59</a>]. Facemasks with a horizontal aerosol path from the device to the face are preferred over those with a vertical aerosol path because they are associated with lower rates of facial and ocular deposition of medication [<a href="#rid4">4,55</a>].</p><p>Delivery of <a class="drug drug_pediatric" data-topicid="13319" href="/z/d/drug information/13319.html" rel="external">fluticasone</a> propionate via a pMDI with an antistatic valved holding chamber is similar when using either a mouthpiece or facemask in children up to nine years of age, and both are associated with higher delivery compared with direct actuation into the mouth [<a href="#rid60">60</a>]. These devices are associated with higher systemic concentrations of glucocorticoids and an increased risk of side effects, particularly with higher drug doses. Thus, doses should be adjusted to the lowest that maintains asthma control.</p><p>Poor patient cooperation leads many caregivers to use blow-by techniques for aerosol delivery of nebulized medications. However, removing the facemask 1 or 2 cm from the face may reduce the inspired dose by approximately 33 and 50 percent, respectively [<a href="#rid39">39,61</a>]. When a facemask is used either with a spacer or nebulizer, it should be placed snugly and tightly fitted over the face, as even a small leak may reduce the inhaled mass of drug to &lt;0.5 percent of the total dose [<a href="#rid62">62</a>].</p><p>The nose is an efficient filter for particles in aerosol [<a href="#rid63">63</a>]. Thus, when using a facemask, any nose breathing is associated with increased deposition in the upper airway. This may lead to more systemic side effects due to greater drug absorption from the upper airway. This is an area of concern for aerosols delivered through nasal cannulas [<a href="#rid44">44</a>].</p><p>Specific aspects of aerosolized medication delivery using nebulizers, pMDIs and soft mist inhalers (SMIs), and DPIs are presented separately. (See  <a class="medical medical_review" href="/z/d/html/5736.html" rel="external">"Use of medication nebulizers in children"</a> and  <a class="medical medical_review" href="/z/d/html/5738.html" rel="external">"The use of inhaler devices in children"</a>.)</p><p class="headingAnchor" id="H14"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/16116.html" rel="external">"Patient education: How to use your child's dry powder inhaler (The Basics)"</a> and  <a class="medical medical_basics" href="/z/d/html/16115.html" rel="external">"Patient education: How to use your child's metered dose inhaler (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/1173.html" rel="external">"Patient education: Asthma inhaler techniques in children (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/z/d/html/1222.html" rel="external">"Patient education: Asthma symptoms and diagnosis in children (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H5426330"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of aerosol delivery devices</strong> – There are three main types of aerosol delivery devices used in the management of children with respiratory disease: nebulizers, pressurized metered dose inhalers (pMDIs) and soft mist inhalers (SMIs), and dry powder inhalers (DPIs). (See <a class="local">'Types of aerosol delivery devices'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Factors affecting drug deposition</strong> – Factors that affect drug deposition include properties of the device, aerosol particle, and medication and patient factors such as disease state, ventilatory pattern, and administration technique. (See <a class="local">'Factors affecting drug deposition'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dose adjustment</strong> – In general, aerosol doses do not need to be decreased except possibly in infants and young children. (See <a class="local">'Dose'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Respiratory pattern</strong> – Normal tidal breathing results in the most efficient delivery to the airways. Crying markedly reduces aerosol delivery to the lungs. Administering the aerosolized medication while the infant/young child is asleep can be attempted, but the child often awakens and becomes distressed. (See <a class="local">'Respiratory pattern'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Administration techniques</strong> – Administration of aerosols by a mouthpiece rather than a facemask is generally preferred due to decreased ocular and facial exposure. Blow-by techniques significantly decrease the inspired dose and are discouraged. (See <a class="local">'Interface'</a> above.)</p><p></p><p class="headingAnchor" id="H2284688419"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Robert H Moore, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Gardenshire DS, Burnett D, Strickland S, Myers TR. A guide to aerosol delivery devices for repiratory therapists, 4th ed. American Association for Respiratory Care, 2017. https://www.aarc.org/education/online-courses/aerosol-devices/ (Accessed on July 05, 2022).</li><li class="breakAll">Berlinski A. Delivery of inhaled medications. In: Pediatric Pulmonology, Asthma, and Sleep Medicine: A Quick Reference Guide, Stokes DC, Dozor AJ, Brooks LJ, et al (Eds), American Academy of Pediatrics, 2018.</li><li class="breakAll">Berlinski A. Neonatal and pediatric inhalation drug delivery. In: Inhalation Aerosols: Physical and Biological Basis for Therapy, 3rd ed, Hickey AJ, Mansour HM (Eds), CRC Press, 2019.</li><li class="breakAll">Berlinski A. Aerosol therapy. In: Foundations in Neonatal and Respiratory Care, 2nd ed, Volsko TE, Barnhart SL (Eds), Jones &amp; Bartlett Learning, 2022. p.451.</li><li><a class="nounderline abstract_t">Fink JB. Aerosol device selection: evidence to practice. Respir Care 2000; 45:874.</a></li><li><a class="nounderline abstract_t">Dolovich MA, MacIntyre NR, Anderson PJ, et al. Consensus statement: aerosols and delivery devices. American Association for Respiratory Care. Respir Care 2000; 45:589.</a></li><li><a class="nounderline abstract_t">Hess D. Aerosol therapy. Respir Care Clin N Am 1995; 1:235.</a></li><li><a class="nounderline abstract_t">Roche N, Huchon GJ. Rationale for the choice of an aerosol delivery system. J Aerosol Med 2000; 13:393.</a></li><li><a class="nounderline abstract_t">Laube BL. Aerosolized Medications for Gene and Peptide Therapy. Respir Care 2015; 60:806.</a></li><li><a class="nounderline abstract_t">Osowicka M, Janowiak P, Gorzewska A, Lichodziejewska-Niemierko M. Inhaled opioids for cancer pain relief: A narrative review. Medicine (Baltimore) 2022; 101:e28921.</a></li><li><a class="nounderline abstract_t">Rubin BK. Experimental macromolecular aerosol therapy. Respir Care 2000; 45:684.</a></li><li><a class="nounderline abstract_t">Newhouse MT, Corkery KJ. Aerosols for systemic delivery of macromolecules. Respir Care Clin N Am 2001; 7:261.</a></li><li><a class="nounderline abstract_t">Rubin BK, Fink JB. Aerosol therapy for children. Respir Care Clin N Am 2001; 7:175.</a></li><li><a class="nounderline abstract_t">Everard ML. Aerosol delivery in infants and young children. J Aerosol Med 1996; 9:71.</a></li><li><a class="nounderline abstract_t">Cole CH. Special problems in aerosol delivery: neonatal and pediatric considerations. Respir Care 2000; 45:646.</a></li><li><a class="nounderline abstract_t">Brocklebank D, Ram F, Wright J, et al. Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature. Health Technol Assess 2001; 5:1.</a></li><li><a class="nounderline abstract_t">Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation therapies. Eur Respir J 2011; 37:1308.</a></li><li><a class="nounderline abstract_t">O'Callaghan C, Barry PW. Asthma drug delivery devices for children. BMJ 2000; 320:664.</a></li><li><a class="nounderline abstract_t">Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. J Allergy Clin Immunol Pract 2022; 10:S1.</a></li><li><a class="nounderline abstract_t">Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187:680.</a></li><li><a class="nounderline abstract_t">Atag E, Unal F, Arslan H, et al. The effect of nebulized antibiotics in children with tracheostomy. Int J Pediatr Otorhinolaryngol 2021; 143:110665.</a></li><li><a class="nounderline abstract_t">Hill NS, Preston IR, Roberts KE. Inhaled Therapies for Pulmonary Hypertension. Respir Care 2015; 60:794.</a></li><li><a class="nounderline abstract_t">Liao Q, Lam JKW. Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses. Curr Pharm Des 2021; 27:1453.</a></li><li><a class="nounderline abstract_t">Quinn M, Fannin JT, Sciasci J, et al. Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Diot P, Dequin PF, Rivoire B, et al. Aerosols and anti-infectious agents. J Aerosol Med 2001; 14:55.</a></li><li><a class="nounderline abstract_t">Gilbert BE. Liposomal aerosols in the management of pulmonary infections. J Aerosol Med 1996; 9:111.</a></li><li><a class="nounderline abstract_t">Roth C, Gebhart J, Just-Nübling G, et al. Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis. Infection 1996; 24:354.</a></li><li><a class="nounderline abstract_t">Simonds AK, Newman SP, Johnson MA, et al. Alveolar targeting of aerosol pentamidine. Toward a rational delivery system. Am Rev Respir Dis 1990; 141:827.</a></li><li><a class="nounderline abstract_t">Willson DF. Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics. Respir Care 2015; 60:774.</a></li><li><a class="nounderline abstract_t">Sherman JM. Breaking the cycle: lidocaine therapy for habit cough. J Fla Med Assoc 1997; 84:308.</a></li><li><a class="nounderline abstract_t">Cohen SP, Dawson TC. Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis. Pediatrics 2002; 110:e38.</a></li><li><a class="nounderline abstract_t">Alton EW, Armstrong DK, Ashby D, et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med 2015; 3:684.</a></li><li><a class="nounderline abstract_t">Brain JD, Valberg PA. Deposition of aerosol in the respiratory tract. Am Rev Respir Dis 1979; 120:1325.</a></li><li><a class="nounderline abstract_t">Dolovich M, Smaldone GC. Estimating the particle size characteristics of therapeutic aerosols. J Aerosol Med 1999; 12:215.</a></li><li><a class="nounderline abstract_t">Darquenne C. Aerosol deposition in health and disease. J Aerosol Med Pulm Drug Deliv 2012; 25:140.</a></li><li><a class="nounderline abstract_t">Darquenne C. Deposition Mechanisms. J Aerosol Med Pulm Drug Deliv 2020; 33:181.</a></li><li><a class="nounderline abstract_t">Le Souëf P. The meaning of lung dose. Allergy 1999; 54 Suppl 49:93.</a></li><li><a class="nounderline abstract_t">Amirav I, Balanov I, Gorenberg M, et al. Beta-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants. J Nucl Med 2002; 43:487.</a></li><li><a class="nounderline abstract_t">O'Callaghan C. Delivery systems: the science. Pediatr Pulmonol Suppl 1997; 15:51.</a></li><li><a class="nounderline abstract_t">Price DB, Román-Rodríguez M, McQueen RB, et al. Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes. J Allergy Clin Immunol Pract 2017; 5:1071.</a></li><li><a class="nounderline abstract_t">Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement Team (ADMIT). Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time? Chest 2016; 150:394.</a></li><li><a class="nounderline abstract_t">Plaza V, Giner J, Rodrigo GJ, et al. Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review. J Allergy Clin Immunol Pract 2018; 6:987.</a></li><li><a class="nounderline abstract_t">Sanders MJ, Bruin R. Are we misleading users of respiratory spacer devices? Prim Care Respir J 2013; 22:466.</a></li><li><a class="nounderline abstract_t">Berlinski A. Pediatric Aerosol Therapy. Respir Care 2017; 62:662.</a></li><li><a class="nounderline abstract_t">Barry PW, O'Callaghan C. Nebuliser therapy in childhood. Thorax 1997; 52 Suppl 2:S78.</a></li><li><a class="nounderline abstract_t">Collis GG, Cole CH, Le Souëf PN. Dilution of nebulised aerosols by air entrainment in children. Lancet 1990; 336:341.</a></li><li><a class="nounderline abstract_t">Onhøj J, Thorsson L, Bisgaard H. Lung deposition of inhaled drugs increases with age. Am J Respir Crit Care Med 2000; 162:1819.</a></li><li><a class="nounderline abstract_t">Rubin BK. Air and soul: the science and application of aerosol therapy. Respir Care 2010; 55:911.</a></li><li><a class="nounderline abstract_t">Kradjan WA, Lakshminarayan S. Efficiency of air compressor-driven nebulizers. Chest 1985; 87:512.</a></li><li><a class="nounderline abstract_t">Iles R, Lister P, Edmunds AT. Crying significantly reduces absorption of aerosolised drug in infants. Arch Dis Child 1999; 81:163.</a></li><li><a class="nounderline abstract_t">Wildhaber JH, Dore ND, Wilson JM, et al. Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children. J Pediatr 1999; 135:28.</a></li><li><a class="nounderline abstract_t">Janssens HM, van der Wiel EC, Verbraak AF, et al. Aerosol therapy and the fighting toddler: is administration during sleep an alternative? J Aerosol Med 2003; 16:395.</a></li><li><a class="nounderline abstract_t">Esposito-Festen J, Ijsselstijn H, Hop W, et al. Aerosol therapy by pressured metered-dose inhaler-spacer in sleeping young children: to do or not to do? Chest 2006; 130:487.</a></li><li><a class="nounderline abstract_t">Geller DE. Clinical side effects during aerosol therapy: cutaneous and ocular effects. J Aerosol Med 2007; 20 Suppl 1:S100.</a></li><li><a class="nounderline abstract_t">Sangwan S, Gurses BK, Smaldone GC. Facemasks and facial deposition of aerosols. Pediatr Pulmonol 2004; 37:447.</a></li><li><a class="nounderline abstract_t">Harris KW, Smaldone GC. Facial and ocular deposition of nebulized budesonide: effects of face mask design. Chest 2008; 133:482.</a></li><li><a class="nounderline abstract_t">Lowenthal D, Kattan M. Facemasks versus mouthpieces for aerosol treatment of asthmatic children. Pediatr Pulmonol 1992; 14:192.</a></li><li><a class="nounderline abstract_t">Mellon M, Leflein J, Walton-Bowen K, et al. Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma. Am J Respir Crit Care Med 2000; 162:593.</a></li><li><a class="nounderline abstract_t">Amirav I, Newhouse MT. Review of optimal characteristics of face-masks for valved-holding chambers (VHCs). Pediatr Pulmonol 2008; 43:268.</a></li><li><a class="nounderline abstract_t">El Mallah MK, Hendeles L. Delivery of medications by metered dose inhaler through a chamber/mask to young children with asthma. Pediatr Allergy Immunol Pulmonol 2012; 25:236.</a></li><li><a class="nounderline abstract_t">Restrepo RD, Dickson SK, Rau JL, Gardenhire DS. An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing. Respir Care 2006; 51:56.</a></li><li><a class="nounderline abstract_t">Erzinger S, Schueepp KG, Brooks-Wildhaber J, et al. Facemasks and aerosol delivery in vivo. J Aerosol Med 2007; 20 Suppl 1:S78.</a></li><li><a class="nounderline abstract_t">Chua HL, Collis GG, Newbury AM, et al. The influence of age on aerosol deposition in children with cystic fibrosis. Eur Respir J 1994; 7:2185.</a></li></ol></div><div id="topicVersionRevision">Topic 5737 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.aarc.org/education/online-courses/aerosol-devices/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Gardenshire DS, Burnett D, Strickland S, Myers TR. A guide to aerosol delivery devices for repiratory therapists, 4th ed. American Association for Respiratory Care, 2017. https://www.aarc.org/education/online-courses/aerosol-devices/ (Accessed on July 05, 2022).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Berlinski A. Delivery of inhaled medications. In: Pediatric Pulmonology, Asthma, and Sleep Medicine: A Quick Reference Guide, Stokes DC, Dozor AJ, Brooks LJ, et al (Eds), American Academy of Pediatrics, 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Berlinski A. Neonatal and pediatric inhalation drug delivery. In: Inhalation Aerosols: Physical and Biological Basis for Therapy, 3rd ed, Hickey AJ, Mansour HM (Eds), CRC Press, 2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="javascript:alert('بدون لینک');" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Berlinski A. Aerosol therapy. In: Foundations in Neonatal and Respiratory Care, 2nd ed, Volsko TE, Barnhart SL (Eds), Jones &amp; Bartlett Learning, 2022. p.451.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10926386" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Aerosol device selection: evidence to practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894452" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Consensus statement: aerosols and delivery devices. American Association for Respiratory Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9390861" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Aerosol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11262446" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Rationale for the choice of an aerosol delivery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070576" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Aerosolized Medications for Gene and Peptide Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35758345" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Inhaled opioids for cancer pain relief: A narrative review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894461" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Experimental macromolecular aerosol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517023" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Aerosols for systemic delivery of macromolecules.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11517020" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Aerosol therapy for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10160211" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Aerosol delivery in infants and young children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10894457" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Special problems in aerosol delivery: neonatal and pediatric considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11701099" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Comparison of the effectiveness of inhaler devices in asthma and chronic obstructive airways disease: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21310878" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : What the pulmonary specialist should know about the new inhalation therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10710559" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Asthma drug delivery devices for children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34718211" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23540878" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33713930" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : The effect of nebulized antibiotics in children with tracheostomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070575" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Inhaled Therapies for Pulmonary Hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33388013" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Inhaled Antifungal Agents for the Treatment and Prophylaxis of Pulmonary Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29866879" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pentamidine for Prophylaxis against Pneumocystis jirovecii Pneumonia in Pediatric Oncology Patients Receiving Immunosuppressive Chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11495486" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Aerosols and anti-infectious agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10160201" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Liposomal aerosols in the management of pulmonary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8923045" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Characterization of amphotericin B aerosols for inhalation treatment of pulmonary aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2327646" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Alveolar targeting of aerosol pentamidine. Toward a rational delivery system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26070574" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Aerosolized Surfactants, Anti-Inflammatory Drugs, and Analgesics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9260434" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Breaking the cycle: lidocaine therapy for habit cough.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12205288" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Nebulized morphine as a treatment for dyspnea in a child with cystic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26149841" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/391112" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Deposition of aerosol in the respiratory tract.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724636" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Estimating the particle size characteristics of therapeutic aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22686623" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Aerosol deposition in health and disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32598200" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Deposition Mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10422755" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The meaning of lung dose.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11937592" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Beta-agonist aerosol distribution in respiratory syncytial virus bronchiolitis in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9316103" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Delivery systems: the science.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28286157" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Inhaler Errors in the CRITIKAL Study: Type, Frequency, and Association with Asthma Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27060726" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Systematic Review of Errors in Inhaler Use: Has Patient Technique Improved Over Time?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29355645" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Errors in the Use of Inhalers by Health Care Professionals: A Systematic Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24270363" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Are we misleading users of respiratory spacer devices?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28546371" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Pediatric Aerosol Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9155859" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Nebuliser therapy in childhood.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1975336" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dilution of nebulised aerosols by air entrainment in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11069819" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Lung deposition of inhaled drugs increases with age.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20587104" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Air and soul: the science and application of aerosol therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3979140" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Efficiency of air compressor-driven nebulizers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10490528" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Crying significantly reduces absorption of aerosolised drug in infants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10393600" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Inhalation therapy in asthma: nebulizer or pressurized metered-dose inhaler with holding chamber? In vivo comparison of lung deposition in children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14977430" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Aerosol therapy and the fighting toddler: is administration during sleep an alternative?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16899849" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Aerosol therapy by pressured metered-dose inhaler-spacer in sleeping young children: to do or not to do?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17411401" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Clinical side effects during aerosol therapy: cutaneous and ocular effects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095329" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Facemasks and facial deposition of aerosols.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18071018" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Facial and ocular deposition of nebulized budesonide: effects of face mask design.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1480446" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Facemasks versus mouthpieces for aerosol treatment of asthmatic children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10934092" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Comparable efficacy of administration with face mask or mouthpiece of nebulized budesonide inhalation suspension for infants and young children with persistent asthma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18219694" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Review of optimal characteristics of face-masks for valved-holding chambers (VHCs).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Delivery of medications by metered dose inhaler through a chamber/mask to young children with asthma</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16381619" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : An investigation of nebulized bronchodilator delivery using a pediatric lung model of spontaneous breathing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17411409" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Facemasks and aerosol delivery in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7713202" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : The influence of age on aerosol deposition in children with cystic fibrosis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
